Publicaciones en colaboración con investigadores/as de Universidad de Castilla-La Mancha (15)

2023

  1. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257

2022

  1. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  2. ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

    Cancers, Vol. 14, Núm. 14

  3. Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers

    Cancers, Vol. 14, Núm. 18

  4. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

2020

  1. An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy

    Pharmaceutics, Vol. 12, Núm. 9, pp. 1-20

  2. Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment

    International Journal of Molecular Sciences, Vol. 21, Núm. 17, pp. 1-21

2019

  1. Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models

    ACS Omega, Vol. 4, Núm. 8, pp. 13005-13014

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. BAX and BCL-2 polymorphisms, as predictors of proliferative vitreoretinopathy development in patients suffering retinal detachment: The Retina 4 project

    Acta Ophthalmologica, Vol. 93, Núm. 7, pp. e541-e549

2013

  1. The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy

    PLoS ONE, Vol. 8, Núm. 12

  2. The p53 codon 72 polymorphism (rs1042522) is associated with proliferative vitreoretinopathy: The retina 4 project

    Ophthalmology, Vol. 120, Núm. 3, pp. 623-628

2007

  1. An update into the pathophysiological role of HER2 in cancer: Therapeutic implications

    Clinical and Translational Oncology